



CASE
COMPREHENSIVE
CANCER CENTER



A Cancer Center Designated by the
National Cancer Institute

**San Antonio Breast Cancer Symposium
(Virtual)**

Dec 8-11, 2020

<https://www.sabcs.org/Program/Schedule-at-a-Glance>

[Click Here to Access SABCS abstracts \(excluding those embargoed\)](#)

****Case CCC Members in BOLD****

Events listed in Eastern Standard Time (EST)

Spotlight Poster Discussion 5 – Thursday, December 10, 2020: 3:15 pm – 4:30 pm

Current Concepts and Controversies in Ductal Carcinoma in Situ (DCIS)

PD5-04: DCIS biosignature reclassified patients who met RTOG 9804 or ECOG-ACRIN E5194 ‘low-risk’ clinicopathologic criteria into an elevated invasive risk group who benefited significantly from radiation therapy

Vicini F, **Shah C**, Shivers S, He W, Karlsson P, Holmberg E, Leo MC, Huang Y, Weinmann S, Warnberg F, Bremer T.

21st Century Oncology, Farmington Hills, MI; Cleveland Clinic, Cleveland, OH; PreludeDx, Laguna Hills, CA. University of South Florida College of Public Health, Tampa, FL; University of Gothenburg, Gothenburg, Sweden; Kaiser Permanente Northwest Center for Health Research, Portland, OR; University of Gothenburg, Uppsala, Sweden.

Poster Session 1 – Wednesday, December 9: 9:00 am

Radiation Therapy

PS1-14: Impact of axillary dissection and patterns of care in patients with ypN1 triple negative breast cancer receiving regional nodal irradiation

Kharouta M, Damico N, Miller M, Harris E, **Lyons J**.

University Hospitals Cleveland Medical Center, Cleveland, OH.

PS1-35: Combined primary site resection and metastasectomy in patients with metastatic breast cancer

Bilani N, Elson L, Liang H, Elimimian E, Nahleh Z.

Cleveland Clinic Florida, Weston, FL.

Axillary Nodes, Surgery

PS1-15: Does breast cancer subtype impact margin status in patients undergoing partial mastectomy?

Fenton A, Dupont E, Tsangaris T, Garcia-Cantu C, Howard-McNatt M, Chiba A, Berger A, Levine E, Gass J, Gallagher K, Lum S, Martinez R, Willis A, Pandya S, Brown E, Mendiola A, Murray M, Solomon N, Senthil M, Ollila D, Edmonson D, Lazar M, Namm J, Li F, Butler M, McGowan N, Herrera M, Avitan Y, Yoder B, Walters L, McPartland T, Haddad V, Ma H, Xie M, Chagpar A.

Cleveland Clinic Akron General, Akron, OH; Watson Clinic, Lakeland, FL; Thomas Jefferson University, Philadelphia, PA; Doctors Hospital at Renaissance, Edinburg, TX; Wake Forest University, Winston-Salem, NC; Women and Infants Hospital, Providence, RI; University of North Carolina, Chapel Hill, NC; Loma Linda University, Loma Linda, CA; Beaumont Hospital, Troy, MI; MicroPath Laboratories, Lakeland, FL; Yale University, New Haven, CT.

Poster Session 2 – Wednesday, December 9: 9:00 am

Markers, Pathology

PS2-12: Can oncotype Dx risk categories be predicted in invasive lobular carcinoma?

Glasgow A, Sechrist H, Bomeis P, **Gilmore H**, Harbhajanka A.

University Hospitals Cleveland Medical Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH.

Poster Session 4 – Wednesday, December 9: 9:00 am

Response Prediction Biomarkers I

PS4-45: Computerized image analysis of nuclear morphological features reveals differences in phenotype and prognosis of disease free survival of early stage ER+ breast cancers for South Asian and North American women

Li H, Bera K, Toro P, **Fu P**, Rao V, Siddique S, Harbhajanka A, Sechrist H, Zhang Z, Desai S, Parmar V, **Madabhushi A**.

Case Western Reserve University, Department of Biomedical Engineering, Cleveland, OH; Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, OH; Department of Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India; Department of Surgical Oncology, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India; University Hospitals Cleveland Medical Center, Cleveland, OH;; Nanjing University of Information Science and Technology, Jiangsu Key Laboratory of Big Data Analysis Technique, Nanjing, China.

Poster Session 5 – Wednesday, December 9: 9:00 am

Response Prediction Biomarkers II

PS5-42: Change in intra-lesion heterogeneity on CT predicts long-term survival following treatment with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer (MBC)

Braman N, Kunte S, Bera K, **Abraham J**, Montero A, **Madabhushi A**.

Case Western Reserve University, Cleveland Heights, OH; Cleveland Clinic, Cleveland Heights, OH; University Hospitals Cleveland Medical Center, Cleveland, OH.

Poster Session 6 – Wednesday, December 9: 9:00 am

Prognostic Factors

PS6-15: Mammprint risk stratification associated with presence of circulating tumor cells in breast cancer

Bilani N, Elson L, Liang H, Elimimian E, Nahleh Z.

Cleveland Clinic Florida, Weston, FL.

PS6-16: Outcomes for metaplastic breast cancer differ by histologic subtype

Tadros AB, Sevilimedu V, Zabor E, Giri D, Morrow M, Plitas G.

Memorial Sloan Kettering Cancer Center, New York, NY; Cleveland Clinic, Lerner Research Institute, Cleveland, OH.

PS6-17: Clinical utility of a biologic signature to assess DCIS recurrence risk in patients meeting ‘good-risk’ criteria (RTOG 9804, ECOG 5194): interim analysis of the DCISionRT PREDICT study

Shah C, Vicini F, Shivers SC, Whitworth PW, Patel R, Cox CE, Bremer T.

Cleveland Clinic, Cleveland, OH; 21st Century Oncology, Farmington, MI; PreludeDx, Laguna Hills, CA; Nashville Breast Center, Nashville, TN; Good Samaritan Cancer Center, Los Gatos, CA; University of South Florida, Tampa, FL.

Poster Session 7 – Wednesday, December 9: 9:00 am

Epidemiology

PS7-26: Acute myocardial infarction prevalence and trends in females with active breast cancer

Gad MM, Saad AM.

Cleveland Clinic Foundation, Cleveland, OH.

PS7-42: Clinicopathological follow-up of breast ductal carcinoma in situ diagnosed on biopsies: A single institutional study of 575 patients

Yan M, Bomeis P, **Gilmore H**, Harbhajanka A.

University Hospitals Cleveland Medical Center, Cleveland, OH.

Poster Session 8 – Wednesday, December 9: 9:00 am

Risk Factors and Prevention

PS8-03: Inflammation and coagulation biomarkers associated with physical resilience in older women receiving chemotherapy for early breast cancer

Sedrak MS, Sun C, Muss H, Freedman RA, Magnuson A, Gross CP, Tew WP, Klepin HD, Wildes TM, Dotan E, O'Connor T, Fenton MA, Sharma R, Chapman A, **Owusu C**, Chow S, Kim H, Katheria V, LaBarge M, Dale W, Armenian S, Neuhausen S, Cohen HJ.

City of Hope, Duarte, CA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Dana-Farber Cancer Institute, Boston, MA; University of Rochester, Rochester, NY; Yale School of Medicine, New Haven, CT; Memorial Sloan Kettering Cancer Center, New York, NY; Wake Forest School of Medicine, Winston-Salem, NC; Washington University School of Medicine, St. Louis, MO; Fox Chase Cancer Center, Philadelphia, PA; Roswell Park Cancer Institute, Buffalo, NY; Lifespan Cancer Institute, Providence, RI; Monter Cancer Center of the North Shore-LIJ Cancer Institute, New York, NY; Sidney Kimmel Cancer Center Jefferson Health, Philadelphia, PA; Case Western Reserve Comprehensive Cancer Center, Cleveland, OH; University of Chicago, Chicago, IL; Duke University Medical Center, Durham, NC.

PS8-07: Predictors of 10-year overall survival in patients with breast cancer

Bilani N, Elson L, Liang H, Elimimian E, Nahleh Z.

Cleveland Clinic Florida, Weston, FL.

Poster Session 9 – Wednesday, December 9: 9:00 am

Psychosocial, Quality of Life and Educational Aspects

PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Moy B, Oliveira M, Saura C, Gradishar W, Kim S-B, Brufsky A, Hurvitz S, Ryvo L, Fagnani D, Chan N, Kalmadi SR, **Silverman P**, Delaloge S, Bryce R, Keyvanjah K, Bechuk J, Zhang B, Oestreicher N, Bose R.

Massachusetts General Hospital Cancer Center, Boston, MA; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; University of Ulsan College of Medicine, Seoul, Republic of Korea; Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA; Assuta Ashdod Medical Center, Ashdod, Israel; ASST di Vimercate, Vimercate, Italy; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Ironwood Cancer and Research Center, Chandler, AZ; University Hospitals Cleveland Medical Center, Cleveland, OH; Intitute Gustave Roussy, Villejuif, France; Puma Biotechnology Inc., Los Angeles, CA; Puma Biotechnology Inc., University of California San Francisco, South San Francisco, CA; Washington University School of Medicine, St. Louis, MO.

Poster Session 10 – Wednesday, December 9: 9:00 am

Systemic Therapies I - Targeted

PS10-15: Analysis of systemic therapies following progression on frontline CDK4/6-inhibitor therapy

Martin JM, Handorf EA, Montero AJ, Goldstein LJ.

University Hospitals/Seidman Cancer Center, Cleveland, OH; Fox Chase Cancer Center, Philadelphia, PA.

Poster Session 11 – Wednesday, December 9: 9:00 am

Systemic Therapies II – New

PS11-02: Comprehensive comparative analysis of invasive ductal and lobular breast cancer cases in Great Lakes

Breast Cancer Consortium

Oesterreich S, Nasrazadani A, Zou J, Onger T, Wright M, Tseng G, Ramaswamy B, Lee AV, Williams N, Kruse M. UPMC Hillman Cancer Center, University of Pittsburgh, Magee Womens Research Institute, Pittsburgh, PA; UPMC Hillman Cancer Center, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, PA; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU), Columbus, OH; James Cancer Hospital/The Ohio State University Wexner Medical Center (OSU), Columbus, PA.

PS11-34: Time to completion of breast cancer treatment and survival

Pratt DA, Burneikis T, Tu C, **Grobmyer SR.**

Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.

Poster Session 12 – Wednesday, December 9: 9:00 am

Systemic Therapies III - Endocrine & Immunotherapy

PS12-16: Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer

Baar J, **Abraham J, Budd GT, Silverman P,** Montero A, **Moore H, Fu P, Varadan V,** Ladaika K, Hricik L.

Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH.

PS12-18: Efficacy of everolimus and exemestane for the treatment of metastatic hormone receptor-positive breast cancer in patients previously treated with CDK4/6 inhibitors

Mo H, Renna CE, **Moore HCF, Abraham J,** Kruse ML, Montero AJ, LeGrand SB, **Budd GT.**

Cleveland Clinic, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH.

Poster Session 14 – Wednesday, December 9: 9:00 am

Systemic Therapies V - Tumor Types; Other

PS14-10: Trends in incidence and stage of male breast cancer, 2004-2016: An analysis from the national cancer database

Cao L, Singh R, Sarode AL, Kharouta M, **Shenk R,** Miller ME.

University Hospitals Cleveland Medical Center, Cleveland, OH.

PS14-12: Trends in breast and axillary surgery for T1-T2 male breast cancer: A study from the national cancer database

Singh R, Cao L, Sarode AL, Kharouta M, **Shenk RS,** Miller ME.

University Hospitals, Cleveland, OH.

Poster Session 18 – Wednesday, December 9: 9:00 am

Tumor Biology III

PS18-45: Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer

Philipovskiy A, Dwivedi A, Gamez R, McCallum R, Nahleh Z, Aguilera R, Gaur S.

Texas Tech University Health Science Center, El Paso, TX; Maroone Cancer Center. Cleveland Clinic Florida, Weston, FL; The University of Texas at El Paso. Border Biomedical Research Center, El Paso, TX.

Ongoing Trials Posters – Wednesday, December 9: 9:00 am

Antibody-drug Conjugates

OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

Beckwith HC, Medgyesy DC, **Abraham J**, Nanda R, Tkaczuk KHR, Krop IE, Puztai L, Modi S, Mita MM, Specht JM, Hurvitz SA, Han HS, Kalinsky K, Wilks S, O'Shaughnessy J, Hart LL, Rugo HS, Mitri ZI, Garfin PM, Burris, III HA.

University of Minnesota, Minneapolis, MN; University of Colorado Health, Fort Collins, CO; NSABP Foundation and Cleveland Clinic, Cleveland, OH; University of Chicago, Chicago, IL; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; Yale University Cancer Center, New Haven, CT; Memorial Sloan Kettering Cancer Center, New York, NY; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; University of Washington, Seattle, WA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Moffitt Cancer Center, Tampa, FL; Herbert Irving Comprehensive Cancer Center, New York, NY; Texas Oncology, San Antonio, TX; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Wake Forest Baptist Medical Center, Winston-Salem, NC; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oregon Health and Science University, Portland, OR; Seattle Genetics, Bothell, WA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.